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Abstract
Problem: The central venous catheter (CVC) usage rate in a large urban dialysis clinic
was 34.5% and the Centers for Medicaid and Medicare Services (CMS) goal is 10.7%.
CVC usage is a quality metric monitored by CMS to assess whether dialysis facilities are
providing quality services which can impact reimbursement for the clinic. Failure to meet
this metric can result in a penalty of up to 2% in reimbursement. The purpose of this
quality improvement project was to determine if an interdisciplinary team (IDT)
approach to vascular access planning and care influenced the CVC usage rate by 10% in
three months.
Methods: An observational descriptive design with a retrospective medical record review
was used to evaluate the effectiveness of interventions aimed to decrease CVC utilization
rates in a large urban dialysis clinic. This pilot study evaluated an IDT approach to
permanent vascular access coordination and was completed between June through August
2021.
Results: Pre-implementation of the IDT approach there were (N=57) patients dialyzed
through a CVC and post-implementation there were (N=59). The monthly CVC usage
was compared to the CMS performance goal of 10.7%. A Pearson chi-square test was
performed (𝑥 2 (1)> = 1.775, p = 0.183), and resulted in no statistical significance, but was
clinically significant with lowering the CVC usage rates to 29.31% from 34.50%.
Implications for practice: An IDT approach may be adopted over a longer time to assess
CVC usage rates before starting hemodialysis by addressing patient barriers (i.e., no
insurance, referrals to vascular surgeons).
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Decreasing Central Venous Catheter Usage Rates for the Hemodialysis Patient
In the United States, more than 37 million people are diagnosed with end-stage
renal disease (ESRD) and in many cases, they need dialysis to sustain their life. Patients
can choose hemodialysis (at home, or in the center) or peritoneal dialysis as a treatment
modality. Approximately 726,000 people are on hemodialysis (Centers for Disease
Control and Prevention [CDC], 2019), and 14, 344 people are on peritoneal dialysis
(United States Renal Data System [USRDS], 2020). A kidney transplant may be an
option if certain criteria (i.e., controlled blood pressure, optimal weight for age, and lab
values) are met to be placed on a kidney transplant list, which can take up to five years or
more. As aforementioned, of the number of people who are on hemodialysis, 80% of
those patients initiate hemodialysis with a central venous catheter (CVC) as the primary
access type (Al-Balas et al., 2017). A CVC is a thin tube tunneled under the skin and
inserted into a large vein, usually the subclavian or internal jugular, and allows for
emergent hemodialysis treatment (CDC, 2019). CVC placement provides immediate
access which takes less than an hour to insert and removal takes less than an hour to
complete. For patients who require emergent dialysis, CVCs are usually inserted in the
hospital setting and patients are discharged from the hospital to an outpatient dialysis
clinic where they will either begin the process of permanent vascular access placement,
choose a home or peritoneal dialysis modality for the continuation of treatment, or apply
for kidney transplantation. Once inserted, the CVC can be accessed and de-accessed
frequently for hemodialysis treatments. Even though CVCs are commonly placed,
patients dialyzing with a CVC face many challenges including inadequate lab values,
longer treatment times on the machine, possible bloodstream infections, catheter
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dysfunction (i.e., clotting, dislodging, blockage), thrombosis, and central vein stenosis
(Bream, 2016).
High CVC usage rates are concerning because of the overwhelming complications
associated with patients dialyzing through a CVC. Patient quality of life and mortality is
dependent on the type of access used for hemodialysis (Cohen et al., 2015). The Centers
for Medicare and Medicaid Services (CMS) recommends a CVC usage rate of 10.7% or
lower because it decreases the risk for mortality (CMS, 2019). A noticeable concern was
the CVC utilization rate in a large urban dialysis clinic was 34.5% with an organizational
regional goal of 13% which is 2.3% higher than CMS’s goal of 10.7%. The pilot study
aimed to utilize an IDT approach to lower the CVC usage rate by 10% in three months.
CMS governs the dialysis clinic for reimbursement payment and leads the EndStage Renal Disease Quality Incentive Program (ESRD QIP). The ESRD QIP program
assesses whether high-quality services are provided and links a portion of payment
directly to the performance of quality-of-care measures. If certain performance standards
are not met, then dialysis clinics are reimbursed at a lower rate (CMS, 2020). CMS uses
14 metrics to evaluate quality and if the performance score is sixty to one hundred, then
their performance is deemed to be quality. One of the performance measures which
accounts for 58% of the total score is the type of vascular access used to treat patients
who fall under the clinical care subdomain. Performance scores ranging from zero to
sixty have not met standards and could be assessed a reimbursement penalty of up to two
percent (CMS, 2020).
The pilot study was of interest because of the high number of African American
patients that were dialyzed per month in a large urban dialysis clinic with a CVC. The
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high CVC utilization rate may have been contributed to the inconsistency of not having a
vascular access coordinator (VAC), staffing turnover rates, and the lack of an
interdisciplinary team (IDT) (i.e., medical director (MD), social worker (SW), facility
administrator (FA), nephrologist, and registered nurse/clinical coordinator (RN/CC))
approach to patient care. Nevertheless, the type of vascular access used for hemodialysis
has a bearing on the quality of life and can play a big role in performance scores as it
relates to reimbursement (CMS, 2020; Cohen et al., 2015).
The purpose of the pilot study was to increase the facilitation of African
American patients having an arteriovenous fistula (AVF) or arteriovenous graft (AVG)
placed as the primary permanent vascular access. The pilot study evaluated the effects of
an IDT approach to vascular access planning which included barriers to receiving an
AVF or AVG. The evidence-based practice (EBP) framework used to guide the study
was the IOWA Model. The pilot study aimed to utilize an IDT approach to lower the
CVC utilization rate in a large urban clinic by 10% over three months. The primary
outcome measure of interest was the CVC utilization rate per month over three months.
The secondary outcome measures of interest were the number of patients who had a CVC
removed, and the number of patients who had an AVF and/or AVG placed within one
month over three months. Study question: In African American adults 19-85 years of age
receiving hemodialysis with a CVC, what is the effect of an IDT approach on CVC usage
rate for hemodialysis patients over three months?

Review of Literature
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A literature review was performed using search engines including Medline
EBSCO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Science
Direct, and Google Scholar from the years 2014 through 2020. The search included
keywords such as end-stage renal disease (ESRD), chronic kidney disease, hemodialysis,
vascular access, a central venous catheter (CVC), arteriovenous fistula (AVF),
arteriovenous graft (AVG), interdisciplinary team (IDT), and social determinants of
health (SDOH). A search of the CINAHL database yielded 159 results while Medline
EBSCO yielded 78 results. The Science Direct database yielded 1,805 results with the
exclusion of encyclopedias and book chapters. Google Scholar yielded 6,630 results. No
Boolean operators were used for the search. Inclusion criteria included: African
American patients 19-85 years of age with a CVC as the primary access who may also
have a maturing AVF/AVG, a diagnosis of ESRD, a candidate for vascular access
surgery, three or fewer previous access surgeries, and controlled co-morbid conditions
(i.e., congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), and
Diabetes). Exclusion criteria included: non-African American, less than 19 and older than
85 years of age, acute kidney injury (AKI) diagnosis, not a candidate for vascular access
surgery, three or more previously failed vascular access maturations or permanent
vascular surgeries. A total of twelve publications were selected for the literature review.
The number of articles selected from each search engine are as follows three from
CINAHL, five from Medline EBSCO, two from Science direct, and two from Google
scholar.
ESRD is a slowly progressing condition that affects minorities at a faster rate and
compared to Caucasians, African Americans are 3.7 times more likely to be diagnosed
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with the disease (Christianson et al., 2018). Once a diagnosis has been made, either a
temporary or permanent vascular access is placed to initiate hemodialysis. A CVC is
often the first vascular access placed for outpatient hemodialysis due to ease of insertion,
and immediate access for use; however, an AVF is the gold standard in vascular access
placement due to long years of access survival, fewer complications with usage, and
access patency (Lee, 2017). AVFs are associated with fewer hospitalizations, lower costs,
lower infection rates, and mortality rates but incur higher costs for maintenance due to
the possibility of numerous surgical interventions (Cohen et al., 2015). Lee (2017)
explained disparities exist in the first vascular access placed to initiate hemodialysis in
patients with lower socioeconomic status. The type of access placed at the initiation of
hemodialysis drastically impacts patient health outcomes and quality of life (Lee, 2017).
As aforementioned, an AVF is the standard for vascular access placement and they are
placed at a higher rate for patients who have been under nephrology care and have been
diagnosed with ESRD (Goldfarb-Rumyantzev et al., 2014), consequently, Shah et al.
(2018) states African Americans are more likely to receive no pre-dialysis care. Over
50% of patients with nephrology care before an ESRD diagnosis still initiate
hemodialysis with a CVC (Lee, 2017). The gap in pre nephrology care and vascular
access placement to initiate dialysis may be related to a lack of education regarding
vascular access options, patient denial of kidney failure, in addition to planning and
timing of vascular access referral by the nephrologist (Lee, 2017).
The type of permanent vascular access placed for outpatient hemodialysis impacts
mortality and is dependent on factors such as patient preference, age, education level,
geographic location, insurance type, gender, and existing comorbid conditions
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(Bhattacharya et al., 2015; Lee, 2017; Shah et al., 2018). The factors stated above impact
the timely removal of a CVC. Women have lower rates of AVF placement than men, and
African Americans, in general, utilize AVFs less frequently than whites (Shah et al.,
2018). Patibandla et al. (2014) explained that AVF failure rates are higher in the elderly,
and African Americans living in urban areas have lower odds of AVF placement
predialysis. Regardless of demographics, the type of insurance coverage is also important
to make referrals and assist in the timely scheduling of vascular access appointments with
the surgeon.
Erickson et al. (2018) posit patients without insurance before a diagnosis of
ESRD experience delays in permanent access placement because of Medicare
ineligibility until several months after starting hemodialysis and are less likely to start
treatment with an AVF or AVG. Patients can establish care with a vascular surgeon based
on the type of insurance coverage they receive. Several Medicare and Medicaid plans are
accepted by the vascular access surgeon’s practice however, some hospitals where the
surgery will be performed will not accept certain insurance plans (Erickson et al., 2018).
In addition to insurance disparities, geographic location has been associated with lower
rates of AVF placement in metropolitan areas (Goldfarb-Rumyantzev et al., 2014).
Geographic location is important for patients to access resources and transportation to
appointments. Goldfarb-Rumyantzev et al., (2014) explained that geographic location has
been associated with barriers such as vascular surgeon availability, distance to the closest
vascular access center, patient compliance, and health literacy. Optimizing the care of
ESRD patients receiving dialysis by eliminating barriers in vascular access placement,
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geographic location, and insurance coverage promotes longer life expectancy and better
quality of care.
Exploring patients’ reasons for permanent vascular access refusal should include
addressing patient concerns and providing patient education when planning to transition
from a CVC to an AVF or AVG to make the process simpler and increase compliance.
Griva et al. (2019) identified the top four reasons for permanent access refusal as fear of
needles, perceived cannulation pain, previous negative surgical experience, and failed
AVF or AVG surgery. Other reasons for permanent access refusal mentioned are
perceived body image, waiting for a kidney transplant, older age, physician approval of
CVC utilization, and no bleeding post dialysis treatment with a CVC (Griva et al., 2019).
Consequently, if the patient has negative perceptions of a permanent vascular access
placement and is comfortable with having a CVC often deters patients from
communicating and collaborating with the IDT to move forward in the process of
receiving an AVF access placement. Involving patients in vascular access planning
promotes active participation, shared decision-making, independence, and compliance.
The identified reasons listed above assist the IDT to develop an individualized patient
approach to vascular access planning and care.
The relationship established between the patient and IDT provides early education
about different vascular access options, referral to surgeons, and dangers associated with
long-term CVC use. Evidence shows one additional visit per month from the nephrologist
or nurse practitioner (NP) during the first ninety days can increase vascular access
surgery by at least 5% (Bhattacharya et. al., 2015). An additional visit allows early
referral for AVF or AVG placement which potentially decreases the number of days
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patients dialyze with a CVC (Bhattacharya et al., 2015). The use of AVFs and vascular
access care has dramatically improved since the implementation of the quality
improvement project the Fistula First Breakthrough Initiative (FFBI) by the ESRD
Network and CMS in 2003. CMS sets the AVF prevalence rate to 66% as the national
standard.
Initially, the goal of FFBI was to collect, analyze, and provide education to
increase AVF use to 40% in prevalent hemodialysis patients and 50% in incident patients
while reducing CVC rates (Lee, 2017). The FFBI shifted to Fistula First, Catheter Last
and addresses issues related to vascular access care primarily through vascular access
education and 13 change concepts. The concepts are a step-by-step outline to address
barriers and topics relevant to the placement and continued utilization of a functional
AVF while stressing the importance of a patient-centered approach. A patient-centered
approach focuses on ensuring the right access for the right patient which takes life
expectancy, vascular anatomy, and quality of life into consideration. Furthermore,
engaging in a patient-centered approach to permanent vascular access placement will
decrease the aforementioned barriers and eliminate unnecessary surgeries and numerous
interventional procedures (Lee, 2017).
The financial impact of AVF placement is linked to frequent surgical access
interventions to promote maturation resulting in higher costs. On average, the cost per
patient who initiates hemodialysis with a mature functioning AVF is approximately
$6,500 compared to $16,500 for patients with a CVC (Hirth & Segal, 2018). The cost
does not include surgical interventions related to AVF maturation failure. AVGs have
higher success rates when placed but require more surgical interventions and often fail
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after use. According to Al-Balas et al. (2017), the cost of access-related procedures and
resulting complications is higher in patients who have an AVF versus AVG placed.
CVCs result in more procedural costs, hospitalizations, infections, and utilization of more
resources (Shah et al., 2018).
Vascular access planning and outcomes should consider a patient-specific
approach as an AVF may not be the optimal access for every patient (Cohen et al., 2015).
Vascular access planning and care is a tedious process that involves care coordination
from several interdisciplinary team members for each patient. The use of a VAC with
specific duties has been shown to improve AVF rates significantly while decreasing the
use of AVGs and CVCs. The VAC is an individual with years of dialysis experience who
can organize, multitask, and work independently to coordinate all aspects of permanent
access placement (Al-Balas et al., 2017). Patient and staff education about care and
maintenance is an important aspect of maintaining the life of the vascular access. In a
study conducted by Bhattacharya et al. (2015), the use of a multidisciplinary vascular
access improvement program providing distinct vascular access protocols, algorithms, a
database, and direct communication with nephrologists and vascular access surgeons
increased AVF use by 15%.
The framework used to guide the study was the Iowa Model of Evidence-Based
Practice to promote quality care. This model guided the IDT in making decisions about
clinical and administrative practices that affect quality healthcare (Melnyk & FineoutOverholt, 2019). A large urban dialysis clinic was evaluated and challenged by the
quality metric of decreasing CVC usage rates to meet the organizational regional goal
(13%) and CMS’s goal (10.7%). The alarming number of patients dialyzing through a

CENTRAL VENOUS CATHETER USAGE

12

CVC was a problem-focused trigger and was an organizational priority to meet the
quality standard from CMS to lower the rate. Despite this large urban clinic having an
IDT team in place that focuses on missed treatment and hospitalization rates but does not
focus on vascular access. With this in mind, an IDT approach that focuses on vascular
access placement was a priority for the clinic. A team of stakeholders included the MD,
FA, SW, and a DNP student implementing an IDT approach on vascular access
placement to evaluate and understand the effect of an IDT approach on CVC usage rates
for African American adults 19-85 years of age receiving hemodialysis through CVC
over three months. The literature search provided sufficient evidence to support the pilot
study which was initiated. An IDT approach has been shown to increase AVF and AVG
utilization and decrease CVC rates (Lok &Woo, 2016).
The literature emphasized the importance of an individualized patient approach to
permanent vascular access planning and coordination. An additional visit a month from
the NP or nephrologist per week in the first ninety days has been shown to increase the
AVF rate as well as the use of a VAC (Cohen et al., 2015). Studies conducted by
(Bhattacharya et al., 2015; Goldfarb-Rumyantzev et al., 2014; Lin et al., 2018; Lok &
Woo, 2016) illustrated barriers in vascular access care are prevalent due to patient
preference, insurance, geographic location, age, gender, and lack of education. Central
venous catheter utilization is associated with mortality but is often the first access utilized
despite pre nephrology care before outpatient hemodialysis treatments begin. Vascular
access disparities can be addressed through an IDT approach, educating patients, earlier
referral, and close follow-up. The FFBI provides a framework to address barriers to
permanent vascular access placement which can increase AVF prevalence and reduce
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CVC use (Lee, 2017). Gaps in the literature were the cost of vascular access surgeries
related to AVF maturation and the use of AVGs in patients who initially fail vascular
access placement.
Methods
Design
An observational descriptive design with a retrospective medical record review
was used to evaluate the effectiveness of interventions aimed to decrease CVC utilization
rates for African Americans. This pilot study evaluated an IDT approach to permanent
vascular access coordination and was completed over three months between June 2021
through August 2021.
Setting
The setting was a large urban dialysis clinic with a total of 14 employees which
includes a SW, a dietician, three nurses, and eight patient care technicians with 22
dialysis stations dialyzing 64 patients six days a week. African Americans represented
99% of the total patient population dialyzed at the clinic.
Sample
A convenience sample of 116 patients dialyzing through a CVC was included in
the pilot study. Inclusion criteria were African American patients aged 19-85 with a CVC
as the primary vascular access for hemodialysis who may also have a maturing
AVF/AVG, a diagnosis of ESRD, a candidate for vascular access surgery, three or fewer
vascular access surgeries, and had controlled co-morbid conditions (i.e., congestive heart
failure (CHF), chronic obstructive pulmonary disease (COPD), and Diabetes). Exclusion
criteria were non-African American, less than age 19 and older than 85 years of age,
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diagnosis of acute kidney injury (AKI), not a candidate for vascular access surgery, three
or more previously failed vascular access maturations or permanent vascular surgeries.
Procedures
A team of stakeholders including the MD, FA, SW, the nephrologist, the NP, and
a DNP student began meeting bi-weekly in November 2020 to discuss implementing an
IDT approach to address barriers to early permanent vascular access placement, since
high CVC usage was a problem-focused trigger. Through a retrospective medical record
review, information about patients with a CVC needing permanent vascular access
placement was collected.
Data Collection and Analysis
A data collection instrument was used to obtain demographics such as age,
gender, ethnicity, zip code, and payer status. Other data collected were permanent
vascular access type, any previous vascular access surgeries, reasons for permanent
access placement refusal, reasons for CVC removal delays, and the type of insurance
coverage carried. No personal identifiers were utilized for the study and each patient was
assigned a number to ensure confidentiality. On a password-protected computer,
information was stored and discarded after the study. Descriptive statistics were used for
data analysis.
Approval Process
Approval from the FA at the organization was granted. Other approvals granted
were from the doctoral committee, graduate school, and the university institutional
review board (IRB). There was minimal risk linked to the study as it a was retrospective
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medical record review of the number of patients who had a CVC removed or an AVF or
AVG placed from June 2021 through August 2021.
Results
In June, July, and August of 2020 before implementation of the IDT, a total of
(N=57) patients were dialyzing through a CVC, (n=1) patient had their CVC removed. In
June, July, and August of 2021 after the implementation of the IDT, a total of (N= 59,
100%) patients were dialyzing through a CVC. In June 2021, (N=19, 32.20%) patients
were dialyzing through a CVC, (n=9, 47.37%) patients had permanent vascular access
placed while (n=0) patients had their CVC removed. In July 2021, (N=22, 37.35%)
patients were dialyzing through a CVC, (n=13, 59.09%) patients had permanent vascular
access placed. In August 2021, (N=18, 30.51%) of patients were dialyzing through a
CVC, (n=1, 5.56%) patients had a CVC removed while (n=10, 55.56%) patients had
permanent vascular access placed (see Appendix A and B). Pre and post-IDT
implementation, there was a total population of (N= 116, 100%). There were (n=76,
65.5%) males and (n=40, 34.5%) females which were represented in the study. Patients
ages 20 to 39 (n=15, 12.9%), ages 40 to 49 (n=16, 13.8%), ages 50-59 represented (n=30,
25.9%), ages 60-69 (n=37, 31.9%), and patients 70 years of age and older represented
(n=18, 15.5%) of the sample (see Appendix C). Patients utilizing Medicare and Medicaid
combined represented (n=55, 47.4%), patients utilizing Medicaid only (n=36, 31%),
Medicare only (n=10, 8.6%), Veteran’s insurance combined with Medicare (n=3, 2.6%),
Veteran’s insurance only (n=6, 52%), Private Pay insurance only (n=3, 2.6%), and
Private Pay combined with Medicare (n=3, 2.6%), (see Appendix D). The monthly CVC
usage was calculated pre and post-IDT implementation to understand how the large urban
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dialysis clinic met the CMS performance goal of 10.7% CVC usage per month. The
clinic’s monthly CVC usage rate for June 2020 was 32.08%, July 2020 was 33.33%,
August 2020 was 35.85%, June 2021 was 34.5%, and July 2021 was 28.07%, and August
2021 was 29.31% (see Appendix E). This large urban dialysis clinic was consistently
above the goal of 10.7% by an average of 33.75% pre and post IDT 30.6% monthly,
however, the monthly CVC usage rate of 34.5% was slightly lower.
To understand if implementation of an IDT approach on CVC usages rates for
hemodialysis patients 19 to 85 years of age was effective in lowering the current CVC
usage rate of 34.5%, a Pearson chi-square test was performed. Based on an = 0.05, an
IDT approach to permanent vascular access placement was not statistically significant
(𝑥 2 (1)> = 1.775, p = 0.183) (see Appendix F). There was no statistical significance
between payer status and CVC removal (𝑥 2 (6)> = 1.840, p= 0.934) (see Appendix F).
There was statistical significance between zip code and payer status (𝑥 2 (48)> = 78.353, p
= 0.004) (see Appendix F), and access placement and payer status (𝑥 2 (6)> = 14.802, p =
0.022) (see Appendix F).
Discussion
In adults 19 to 85 years of age receiving HD with a CVC, the effect of an IDT
approach on CVC usage rates for hemodialysis patients over three months did not show
any statistical significance, however, the post-IDT CVC usage rate was trending down
and by August 2021 was 29.31% which is clinically important. This rate was not within
CMS’s national goal of 10.7% or less, but there was a decrease in the CVC usage rate
overall.
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The strengths of this study were the intentionally chosen population of African
American patients and convenient sampling. The results were important because these
patients are at higher risk for access maturation failure, morbidity, mortality, and poor
health outcomes due to low socioeconomic status and an IDT approach could potentially
decrease these risks. Limitations of the study included the availability of vascular access
surgeons in the region, the time the pilot study was initiated (during the COVID-19
pandemic), and patient insurance impediments. While the IDT approach to permanent
vascular access placement results showed no statistical significance, the monthly CVC
usage rate showed some benefits to having an IDT team such as timely scheduling of
appointments and a slight increase in the amount of permanent vascular accesses placed.
Patient barriers such as transportation to appointments, fear of being cannulated with
needles, insurance delays, and the requirement to obtain cardiac clearance before vascular
access surgery remained factors in the IDT approach being successful. Implications for
future practice could be education on risk factors of long-term CVC usage before starting
HD, addressing patient challenges associated with permanent vascular access placement,
insurance verification within the first week of HD, referrals to vascular access surgeons
within the first 30 days of treatment, and permanent vascular access placement within the
first 90 days of treatment. Recommendations for further study might warrant adopting an
IDT approach in more HD clinics and include other ethnic backgrounds (i.e., Asian and
Hispanics) in the study.
Conclusion
In summary, the introduction of an IDT approach to CVC usage rates was not
statistically significant (p = 0.183), but it was clinically significant. It is reasonable to
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assume CVC usage rates improve with the implementation of an IDT approach. The
intervention could be useful and implemented in other dialysis clinics to address patient
barriers to permanent vascular access placement and improve CVC usage rates. Overall,
patients on HD dialyzing through a CVC is not desirable but is widely practiced and
more interventions to decrease CVC usage rates are warranted to meet and comply with
CMS goals and standards.
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Appendix A
Figure 1
Permanent vascular access placement and CVC removal by month.
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Appendix B
Figure 2
Number of CVC removals per month
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Appendix C
Figure 3
Number of Study Participants by Age
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Appendix D
Figure 4
Insurance payer status
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Note: MD/MC corresponds to Medicare and Medicaid coverage, MD is Medicaid only, MC is
Medicare only, VA/MC corresponds to Veteran’s insurance with Medicare, VA is Veteran’s
Insurance only, PP is private pay, and PP/MC is private pay with Medicare.
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Appendix E
Figure 5
Monthly CVC usage rate
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Note: The monthly CVC usage rate before IDT implementation is displayed by the blue bars and
after IDT implementation is displayed by the orange bars. Note: The monthly CVC usage rate for
the clinic was obtained as it is compared to CMS goal.
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Appendix F
Table 1
Pearson Chi-Square Test for CVC Removal Post IDT Implementation

Note. N = 116. The value of the test statistic is 1.775. The footnote for this statistic pertains to the
expected cell count assumption (i.e., expected cell counts are greater than 5): 2 cells had an
expected count less than 5, so this assumption was not met. The corresponding p-value of the test
statistic is p = 0.183.
Table 2
Payer Status and CVC removal

Note. N = 116. The value of the test statistic is 1.840. The footnote for this statistic pertains to the
expected cell count assumption (i.e., expected cell counts are greater than 5): 10 cells had an
expected count less than 5, so this assumption was not met. The corresponding p-value of the test
statistic is p = 0.934.
Table 3
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Zip Code and Payer Status

Note. N = 116. The value of the test statistic is 78.353. The footnote for this statistic pertains to
the expected cell count assumption (i.e., expected cell counts are greater than 5): 57 cells had an
expected count less than 5, so this assumption was not met. The corresponding p-value of the test
statistic is p = 0.004.
Table 4
Access Placement and Payer Status

Note. N = 116. The value of the test statistic is 14.802. The footnote for this statistic pertains to
the expected cell count assumption (i.e., expected cell counts are greater than 5): 9 cells had an
expected count less than 5, so this assumption was not met. The corresponding p-value of the test
statistic is p = 0.022.

